title: Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial.
abstract: BACKGROUND
  Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine.
  
  
  METHODS
  A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks. Treatment response was assessed by the Yale-Brown Obsessive-Compulsive Scale (YBOCS), as primary outcome measure, and Clinical Global Impressions-Severity Scale (CGI-S), as a secondary outcome measure.
  
  
  RESULTS
  A total of 27.27% of the cases in the aripiprazole group (n = 6) and 54.54% of them in the quetiapine cluster (n = 12) responded moderately to the aforesaid augmentation. The mean ± SD baseline YBOCS score of 33.27 ± 3.90 dropped to a mean of 30.72 ± 4.67 (p = 0.06) in the aripiprazole group, and from 31.18 ± 4.93 to 27.97 ± 3.71 (p = 0.01) in the quetiapine group, at the end of the evaluation. There was no significant change with respect to CGI-S in either of the aforesaid groups.
  
  
  CONCLUSIONS
  This study shows that treatment-resistant OCD patients may benefit more from addition of quetiapine in comparison with aripiprazole, to their ongoing SRI therapy.
authors: University of Social Welfare and Rehabilitation Sciences (USWR), Razi Psychiatric Hospital, Amin Abad, Shahre Rey, Tehran, Iran.
authors: Saeed
authors: S
authors: Shoja Shafti
authors: Azad University, Iran.
authors: Hamid
authors: H
authors: Kaviani
keywords: aripiprazole; obsessive–compulsive disorder; quetiapine
references: Cochrane Database Syst Rev. 2010 Dec 08;(12 ):CD008141
references: 21154394
references: Clin Pract Epidemiol Ment Health. 2011;7:107-11
references: 21686322
references: Can J Psychiatry. 2001 May;46(4):356-8
references: 11387793
references: Int Clin Psychopharmacol. 2006 Nov;21(6):337-43
references: 17012980
references: Adv Ther. 2011 Apr;28(4):341-8
references: 21437763
references: Arch Gen Psychiatry. 1989 Nov;46(11):1006-11
references: 2684084
references: Hum Psychopharmacol. 2011 Jan;26(1):51-7
references: 21308781
references: Arch Gen Psychiatry. 2000 Aug;57(8):794-801
references: 10920469
references: J Clin Psychiatry. 2004 Aug;65(8):1040-8
references: 15323587
references: Mol Psychiatry. 2006 Jul;11(7):622-32
references: 16585942
references: J Clin Psychopharmacol. 2008 Oct;28(5):550-4
references: 18794652
references: J Clin Psychiatry. 1999 Aug;60(8):524-7
references: 10485634
references: Int Clin Psychopharmacol. 2009 Sep;24(5):265-9
references: 19629012
references: BMC Psychiatry. 2005 Jan 24;5:5
references: 15667657
references: J Psychiatr Res. 2006 Sep;40(6):502-10
references: 16904424
references: Fortschr Neurol Psychiatr. 2011 Aug;79(8):453-66
references: 21809258
references: J Clin Psychopharmacol. 2011 Apr;31(2):174-9
references: 21346614
references: J Clin Psychiatry. 1997;58 Suppl 12:7-10
references: 9393390
references: J Clin Psychiatry. 1997;58 Suppl 4:2-72
references: 9183300